Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborators: Takeda; Takeda Bio Development Center, Ltd
• Treatments: Imatinib Mesylate; Motesanib diphosphate; Niacinamide

Criteria

Inclusion Criteria:

• Diagnosis of histological confirmed GIST

• Had prior imatinib mesylate therapy

• Has at least 1 measurable leasion by modified RECIST

Exclusion Criteria:

• Central nervous system tumor involvement requiring treatment

• History of myocardial infraction

• Uncontrolled hypertension